Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue.

This was the first of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study enrolling approximately 510 patients at more than 60 clinical sites who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

Recently the Company announced that more than 133 patients have been enrolled in its MAESTRO-03 trial. An interim safety and efficacy analysis will be performed on data from the first 133 patients enrolled when they have completed 24 months of the clinical trial.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...re-FirstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),t...nouncedthatithassubmittedaMAAtotheEuropeanMedicine...lacementtherapyindevelopment,forthetreatmentofType...nforvelaglucerasealfathathasbeensubmitted,withprev... Basedonaglobalsupplyshortageofthecurrentlyapprove...
(Date:11/24/2009)... Abstracts Service (CAS), the global expert on che...ice is now the world,s leading producer of patent ... Japan,s patent office, the World Intellectual Pro...atent and Trademark Office (USPTO) for more than a...6, and exceeded Japan for the first time on a mont...
(Date:11/23/2009)...sional carbon layer in which the carbon atoms are ...ycomb. Carbon nanotubes are rolled-up sheets of gr...aphite. Graphene boasts some very special characte...ent thermal conductor, and reconciles such conflic...dition, graphene is impermeable to gases, which ma...
(Date:11/23/2009)...--ImmuneDesignC or p.(IDC)announcedtodaythatDr.Bru...terhasasuccessfultrackrec or dinbiotechnologyexecu...eratZymoGenetics,inSeattle,WAandChiefScientificOff...to: http://www.newscom.com/cgi-bin/prnh/20091123/S...xecutiveOfficercommented,"IamdelightedtowelcomeDr....
Breaking Biology Technology:Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3Polymer with honeycomb structure 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2
...PDS , an IT firm that operates in the Madison and ...nesses who are having trouble keeping track of all...e. , ,"We,ve had IT managers tell us it,s just to...working, especially as more employees are allowed ... infrastructure services for PDS, in a press relea...
... It turns out that "free" services can be profitab...k, LinkedIn, announced that this month it would hi...profitability. , ,After a few years of hooking up ...ntroduced premium services, ranging in cost from $... offerings has exceeded expectations of even the m...
...cientists say it,s not a matter of if, but when. A... the least, keep large sections of the population ...ions and cause infrastructure outages information... coordinating both public efforts and business. , ...ely, they could be left with more than an interrup...
Other Biology Technology:Free can be profitable 2IT critical in pandemic response, but many are not paying attention 2IT critical in pandemic response, but many are not paying attention 3IT critical in pandemic response, but many are not paying attention 4
(Date:11/23/2009)...a biomedical engineer and cardiologist Tzung "John...ians distinguish cardiac emergencies requiring imm...th drugs and lifestyle change. , Angiograms, ima...eeding the heart, offer an inside view of the inte...en revealing deposits of a dangerous fatty substan...
(Date:11/23/2009)... , , , , , , , ...Dr Andrew Marshall, from the Environment Departmen...ry of Kinyongia magomberae and his wider work in...e information. , , , , , ... , , , , , , A new species of chamele...
(Date:11/23/2009)...n Institute for Child Health Research has found ev...mption in pregnancy affects child behaviour in dif... online in the international journal Addiction . ...was drawn from a random sample of more than 2000 m...after the baby,s delivery, and were then followed ...
Breaking Biology News(10 mins):Stable plaque or heart attack plaque? USC researcher builds new sensor to tell which is which 2New chameleon species discovered in East Africa 2New chameleon species discovered in East Africa 3New study links alcohol in pregnancy to child behavior problems 2Type of Knee Surgery Makes Difference in Football Career 51400 1Type of Knee Surgery Makes Difference in Football Career 51400 2Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 1Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 2Mayo Clinic study using structural MRI may help accurately diagnose dementia patients 51393 1Mayo Clinic study using structural MRI may help accurately diagnose dementia patients 51393 2
...loped "self-exploding" microcapsules that could on...the human body weeks or even months after injectio...nd the Universit? Catholique de Louvain, is schedu...the American Chemical Society,s journal Biomacrom...ch release their drug cargo only when exposed to u...
...team believes that changes in behaviour among the ...HIV infection in Eastern Zimbabwe. , Research publ... almost 50 percent decline in HIV prevalence in so...le delaying when they first have sex and having fe...fell most steeply at young ages, with a drop in pr...
...ould provide the next generation of human therapeu...nom has been identified by Queensland University o...dly stop excessive bleeding during vascular surger...xin, Factor X (Factor Ten), was identified by PhD ...e Sciences who studied the venom of eight of Austr...
Other Biology News:HIV decline in Zimbabwe linked to behavioural change 2Taipan venom no snake oil 2
Dynabeads Mouse Pan B (B220) from Dynal Biotech
Rabbit Anti-Human ALS2CR2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Rabbit Anti-Human GORASP2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
FailSafe PCR 2X PreMix B from EPICENTRE Biotechnologies
Biology Products: